In a report released today, Dane Leone from BTIG maintained a Buy rating on Xencor Inc (NASDAQ: XNCR), with a price target of $56. The company’s shares closed on Friday at $38.40.
According to TipRanks.com, Leone is a 5-star analyst with an average return of 19.9% and a 66.0% success rate. Leone covers the Healthcare sector, focusing on stocks such as Voyager Therapeutics Inc, Blueprint Medicines, and G1 Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xencor Inc with a $48.50 average price target.
See today’s analyst top recommended stocks >>
Based on Xencor Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $25.87 million. In comparison, last year the company had a GAAP net loss of $6.89 million.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. Last month, Paul A. Foster, the CMO of XNCR sold 3,659 shares for a total of $146,726.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions.
